Protagenic Therapeutics, Incnew DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Protagenic Therapeutics announces its virtual annual meeting on December 31, 2025, seeking stockholder ratification for a new independent accounting firm and detailing significant board composition changes.
OQB
Protagenic Therapeutics and Phytanix Bio combine in an all-stock transaction to form Phytanix, Inc., a neuroactive biopharmaceutical company with a diverse pipeline.
OQB
Protagenic Therapeutics is asking stockholders to approve a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement and potentially increase investor interest.
OQB
Protagenic Therapeutics issues a supplement to its proxy statement to correct an error in the record date and the number of outstanding shares.
OQB
Protagenic Therapeutics is holding a virtual annual meeting on February 21, 2025, to vote on key proposals including director elections, option repricing, warrant issuance approval, and an equity incentive plan amendment.